BRCA1 and prostate carcinoma: These positive preliminary findings led to the FDA approval of rucaparib in May 2020 for BRCA1/2 mutated metastatic castration-resistant prostate cancer patients who progressed after one to two lines of AR-directed therapy and one taxane-based chemotherapy.